TRVN:OTCMKTS
Trevena Inc
0,066 US$
0,00%
(0,00) 1K
12-okt, 14:57:26 (GMT-4) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoTRVN tikeri uchun statistika yaratilmoqda...
Bozor kapitali
57,01 ming
Oʻrtacha hajm
210,00
Hajmi
9,00
52 haftalik eng yuqori
1,50 US$
52 haftalik eng past
0,00 US$
Beta
1,07
Muomaladagi aksiyalar
864,00 ming
Xodimlar soni
23
Bozor kapitali
57,01 ming
Oʻrtacha hajm
210,00
Hajmi
9,00
52 haftalik eng yuqori
1,50 US$
52 haftalik eng past
0,00 US$
Beta
1,07
Muomaladagi aksiyalar
864,00 ming
Xodimlar soni
23
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Quiver Quantitative
·
34 daqiqa oldin
Private Bancorp of America Reports Third Quarter 2026 Net Income of $11.4 Million and Diluted EPS of $1.97 as Deposits and Loans Grow After NASDAQ Uplisting
The Daily News | Texas' Oldest Newspaper
·
43 daqiqa oldin
FILE PHOTO: Signage is seen outside the New York Stock Exchange (NYSE) in Manhattan, New York City
www.marketscreener.com
·
16 daqiqa oldin
TruGolf Holdings Inc. (NASDAQ: TRUG) Acquisition Positions Company in Market for Regulated Tokenization, Digital Securities Infrastructure
Profil
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
Trevena Inc haqida
CEO-
Xodimlar soni23
Asos solingan2007
Bosh ofislarAtlanta, Jorjiya, Amerika Qo‘shma Shtatlari
Sektor-
Veb-sayttrevena.com